Motley Fool1d agobullish
Is Kailera Therapeutics a Buy After Its Sizzling IPO?There's a new challenger to the more established players in the weight-loss drug space.
Actualités
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
48last 24h
1672last 7d
313🟢 bullish (7d)
171🔴 bearish (7d)
136publishers
Investor's Business Daily5d agoneutral
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityAnalysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.